Skip to main content

Table 5 Response rate according to the clinical factors and the genotypes

From: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

   Overall frequency Responder  
   No. of Pts % No. of Pts RR (%) p-value*
Age ≤ 55 31 42.5 15 48.4 0.501
  > 55 42 57.5 17 40.5  
Performance ECOG 0–1 60 82.2 28 46.7 0.295
  ECOG 2 13 17.8 4 30.8  
Histotype Intestinal 47 67.1 19 40.4 0.557
  Diffuse 23 32.9 11 47.8  
  unknown 3     
Disease status Initial stage IV 54 74.0 27 50.0 0.107
  Relapsed 19 26.0 5 26.3  
TS in 5'UTR# 2R/2R, 2R/3C, 3C/3C 21 28.8 7 33.3 0.285
  2R/3G, 3C/3G, 3G/3G 51 69.9 24 47.1  
  unknown 1 1.4    
TS 6-bp deletion in 3'UTR -6/-6 40 54.8 22 55.0 0.034
  +6/+6 or +6/-6 33 45.2 10 30.3  
GSTP1-Ile105Val (A105G) A/A 44 60.3 22 50.0 0.191
  A/G or G/G 29 39.7 10 34.5  
ERCC-Asn118Asn C/C 40 54.8 17 42.5 0.800
  C/T or T/T 33 45.2 15 57.5  
ERCC-C8092A C/C 44 60.3 18 40.9 0.535
  C/A or A/A 29 39.7 14 48.3  
XPD- Arg156Arg C/C 23 31.5 6 26.1 0.038
  C/A or A/A 50 54.0 26 52.0  
XPD-Asp312Asn G/G 8 11.0 1 12.5 0.072
  G/A 65 89.0 31 47.7  
XPD-Lys751Gln A/A 62 84.9 28 45.2 0.746
  A/C or C/C 11 15.1 4 36.4  
XRCC1-Arg399Gln G/G 48 65.8 21 43.8 0.984
  G/A or A/A 25 34.2 11 44.0  
  1. RR, response rate.
  2. *p-value for the comparison between response rate and genotypes, based on Pearson's χ 2 test (using Fisher's exact test, if N ≤ 5).
  3. #Analysis of the TS-5'UTR VNTR polymorphism with G/C SNP change in 3R allele carriers.